申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2018132279A1
公开(公告)日:2018-07-19
The invention relates generally to compounds of formula (I) that modulate the activity of TGFβR-l and TGFβR-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
这项发明涉及一般公式(I)的化合物,这些化合物调节TGFβR-1和TGFβR-2的活性,包含该化合物的药物组合物以及利用该发明的化合物治疗增殖性疾病和失调凋亡疾病(如癌症)的方法。